Recursion director sells 30K shares at $3.34

A director of RXRX sold 30,000 Class A shares under a pre-arranged Rule 10b5-1 trading plan and continues to hold over 6.1 million shares.

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson sold shares of the company’s Class A Common Stock. On September 1, 2026, he sold 30,000 shares at an average price of $3.34 per share in an open-market or private transaction. Following this sale, he continued to hold 6,158,287 shares of Class A Common Stock directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025, indicating the transaction was pre-arranged under that plan.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares

Net Sell 1 txn

Insider Borgeson Blake

Role Director

Sold 30,000 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	30,000	$3.34	$100K

Holdings After Transaction: Class A Common Stock — 6,158,287 shares (Direct)

Footnotes (1)

1. F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Key Figures

Shares sold: 30,000 shares Sale price per share: $3.34 per share Shares held after transaction: 6,158,287 shares +2 more

5 metrics

Shares sold 30,000 shares Class A Common Stock sold by director on September 1, 2026

Sale price per share $3.34 per share Average price for the 30,000 Class A shares sold on September 1, 2026

Shares held after transaction 6,158,287 shares Director’s direct holdings of Class A Common Stock after the sale

Rule 10b5-1 plan adoption date August 31, 2025 Date the trading plan governing this sale was adopted

Net shares sold in filing 30,000 shares Total net share decrease reported for this Form 4

Key Terms

Rule 10b5-1 trading plan, Class A Common Stock, open-market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Class A Common Stock financial

"The transaction involved Class A Common Stock of RECURSION PHARMACEUTICALS, INC."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market or private transaction financial

"The sale was described as a sale in an open-market or private transaction"

FAQ

Who from RXRX reported a transaction in this Form 4?

The filing reports that director Blake Borgeson of RECURSION PHARMACEUTICALS, INC. engaged in the reported stock transaction involving the company’s Class A Common Stock.

How many RXRX shares did Blake Borgeson sell and at what price?

On September 1, 2026, Blake Borgeson sold 30,000 shares of RXRX Class A Common Stock at an average price of $3.34 per share in an open-market or private transaction.

How many RXRX shares does Blake Borgeson hold after the reported sale?

After the reported transaction, Blake Borgeson directly holds 6,158,287 shares of RECURSION PHARMACEUTICALS, INC. Class A Common Stock, as stated in the filing.

Was the RXRX stock sale by Blake Borgeson under a Rule 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1 trading plan that Blake Borgeson adopted on August 31, 2025, indicating it was pre-arranged under that plan.

What type of security in RXRX was involved in this Form 4?

The transaction involved Class A Common Stock of RECURSION PHARMACEUTICALS, INC., which is the company’s listed common equity class referenced in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 06:02 PM Accepted by SEC EDGAR 09/02/2026 - 06:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/01/2026		S(1)		30,000	D	$3.34	6,158,287	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)